The effects of bumetanide, amiloride and Ba2+ on fluid and electrolyte secretion in rabbit salivary gland.
1. In order to distinguish between models of anion secretion, the effects of transport inhibitors on saliva flow rate and electrolyte composition were studied during the plateau phase of secretion in rabbit mandibular salivary glands. 2. Bumetanide, an inhibitor of Na+,K+,2Cl- co-transport, inhibited flow rate (by 60%) and reduced Cl- concentration. K+ and HCO3- concentrations were increased. Forskolin, an adenylate cyclase activator which inhibits ductal transport, did not significantly affect this pattern of changes. 3. Amiloride, used at concentrations that would inhibit Na(+)-H+ exchange, inhibited flow rate (by 30%). Cl- concentration was initially increased before subsequently decreasing at the same time as HCO3- concentration increased. These concentration changes can probably be attributed to ductal transport. When amiloride was applied to glands perfused with nominally HCO3- -free solutions, inhibition of flow rate was rapid and almost complete. 4. When amiloride and bumetanide were both present in the perfusate, flow rate was inhibited by 92%. The pattern of electrolyte changes was not significantly different from that observed in the presence of bumetanide alone. 5. Inhibition of K+ channel activity using Ba2+ also inhibited flow rate. Cl- concentration was increased as was K+ concentration. HCO3- concentration was not increased. 6. The anion exchange inhibitor DIDS (4,4'-diisothiocyanatostilbene-2,2'-disulphonic acid) had no effect on either flow rate or electrolyte concentration. It did, however, elicit secretion in the absence of acetylcholine. 7. The data suggest that Na(+)-H+ and Cl- -HCO3- exchangers are unlikely to be involved in fluid and electrolyte secretion in these glands as suggested by some authors. Most of the data can be explained by postulating the existence of non-specific anion channels in the apical membranes of the acinar cells.
Department of Physiological Sciences, University of Manchester.
K R
KR
Lau
A J
AJ
Howorth
R M
RM
Case
D017878:4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid; D012856:4-Acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic Acid / Q000031:analogs & derivatives / Q000494:pharmacology; D000109:Acetylcholine / Q000378:metabolism; D000584:Amiloride / Q000494:pharmacology*; D000818:Animals; D001464:Barium / Q000494:pharmacology*; D001639:Bicarbonates / Q000378:metabolism; D002034:Bumetanide / Q000494:pharmacology*; D002712:Chlorides / Q000378:metabolism; D005576:Colforsin / Q000494:pharmacology; D004573:Electrolytes / Q000378:metabolism*; D006863:Hydrogen-Ion Concentration; D007474:Ion Exchange; D008297:Male; D011817:Rabbits; D012469:Salivary Glands / Q000187:drug effects / Q000378:metabolism*; D012964:Sodium / Q000378:metabolism
D001639:Bicarbonates; D002712:Chlorides; D004573:Electrolytes; D002034:Bumetanide; D005576:Colforsin; D001464:Barium; D012856:4-Acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic Acid; D000584:Amiloride; D012964:Sodium; D000109:Acetylcholine; D017878:4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid